Achieving systemic delivery of oncolytic viruses
<p><strong>Introduction:</strong> Oncolytic virotherapy is a selective and powerful tool for cancer treatment. Studies proving the ability of oncolytic viruses (OVs) to target and rapidly kill cancer cells have led to approval of H101 and Imlygic®. Both these OVs are restricted to...
| المؤلفون الرئيسيون: | , |
|---|---|
| التنسيق: | Journal article |
| اللغة: | English |
| منشور في: |
Taylor and Francis
2019
|